甲状腺治疗中使用的131碘胶囊：与液态131碘相比，对其摄取动力学的个体对照研究。

131-Iodine capsules in thyroid therapy: an individually controlled study of their uptake kinetics as compared to liquid 131-iodine.

作者信息

von Schulthess G K, Seelentag W W, Pfeiffer G, Blaeuenstein P, Bekier A

出版信息

Eur J Nucl Med. 1985;10(1-2):25-8. doi: 10.1007/BF00261758.

Abstract

We investigated the uptake of therapeutic doses of 131-Iodine in capsular form which were given to 16 patients with benign thyroid disease, and compared it to the uptake of a diagnostic dose of liquid 131-Iodine given to the same patients. The aim of this study was to determine the additional radiation dose sustained by the gastric mucosa, and thus, to establish the safety of this galenic form of 131I. It was found that the average capsule-dissolution time was about 12 min, with a large standard deviation of about 7 min. Using these data and a theoretical radiation-dose calculation, we estimated that the maximum dose to the gastric mucosa was approximately 250 rad (250 cGy) for a therapeutic activity of 5 mCi (185 MBq), which is the maximum dose which may be given as single application to out-patients in Switzerland. Thus, 131I administered in capsular form is a safe galenic form for therapeutic use in patients with thyroid disease.

摘要

我们研究了16例患有良性甲状腺疾病的患者服用治疗剂量的胶囊形式的131碘后的摄取情况，并将其与这些患者服用诊断剂量的液态131碘后的摄取情况进行了比较。本研究的目的是确定胃黏膜所承受的额外辐射剂量，从而确定这种131碘剂型的安全性。结果发现，胶囊平均溶解时间约为12分钟，标准偏差约为7分钟。利用这些数据和理论辐射剂量计算，我们估计，对于5毫居里（185兆贝可）的治疗活度，胃黏膜的最大剂量约为250拉德（250厘戈瑞），这是瑞士门诊患者单次给药的最大剂量。因此，胶囊形式的131碘是用于甲状腺疾病患者治疗的一种安全剂型。